{"id":719,"date":"2020-09-03T13:54:20","date_gmt":"2020-09-03T20:54:20","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=719"},"modified":"2020-09-08T13:55:03","modified_gmt":"2020-09-08T20:55:03","slug":"phase-1-2-trial-of-a-sars-cov-2-recombinant-spike-protein-nanoparticle-vaccine","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/09\/03\/phase-1-2-trial-of-a-sars-cov-2-recombinant-spike-protein-nanoparticle-vaccine\/","title":{"rendered":"Phase 1\u20132 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine"},"content":{"rendered":"<ul>\n<li>NVX-CoV2373, a recombinant nanoparticle vaccine, induced higher levels of anti-spike IgG and neutralizing antibody responses compared to convalescent serum of mostly symptomatic COVID-19 patients. There were no serious adverse events, and events such as fever and sore arm were mild and not long-lasting. These results were from a primary analysis at day 35 of a randomized control trial (n=83).<em> [EDITORIAL NOTE: A summary of a pre-print version of this manuscript appeared in the Lit Rep on August 6]<\/em><\/li>\n<\/ul>\n<p><em>Keech et al. (Sept 2, 2020). Phase 1\u20132 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. New England Journal of Medicine. <a href=\"https:\/\/doi.org\/10.1056\/NEJMoa2026920\">https:\/\/doi.org\/10.1056\/NEJMoa2026920<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>NVX-CoV2373, a recombinant nanoparticle vaccine, induced higher levels of anti-spike IgG and neutralizing antibody responses compared to convalescent serum of mostly symptomatic COVID-19 patients. There were no serious adverse events, and events such as fever and sore arm were mild and not long-lasting. These results were from a primary analysis at day 35 of a&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/09\/03\/phase-1-2-trial-of-a-sars-cov-2-recombinant-spike-protein-nanoparticle-vaccine\/\">Read more<\/a><\/div>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[28],"topic":[31],"class_list":["post-719","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-treatment","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/719","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=719"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/719\/revisions"}],"predecessor-version":[{"id":720,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/719\/revisions\/720"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=719"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=719"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=719"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=719"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}